On July 17, Hengrui Medicine fell 3.19% in regular trading, trading at 55.75 HKD/share, with turnover of approximately 68.17 million HKD. The decline came amid broad-based weakness across the pharmaceutical sector.

The Pharmaceuticals sector where Hengrui belongs experienced significant selling pressure, with major peers declining sharply: Asymchem down 7.69%, China Biopharmaceutical down 5.32%, Luye Pharma down 4.5%, CSPC Pharmaceutical down 4.3%, and Hansoh Pharmaceutical down 3.56%. The sector-wide retreat overshadowed recent positive pipeline developments, including the company's July 16 approval to conduct Phase III clinical trials for HRS9531 injection in obese patients with knee osteoarthritis, building on cumulative R&D investment of approximately 701 million yuan. Lingering pressure from the FDA's third Complete Response Letter for camrelizumab combination therapy, disclosed on July 10, citing cGMP manufacturing facility inspection issues, may also continue to weigh on sentiment despite the company clarifying no concerns were raised regarding clinical efficacy or safety data.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)